Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India

Maria L. Ekstrand, Anita Shet, Sara Chandy, Girija Singh, Ranjani Shamsundar, Vidya Madhavan, Shanmugam Saravanan, Elsa Heylen, Nagalingeswaran Kumarasamy

Research output: Contribution to journalArticle

Abstract

This study was conducted to examine the relationship between adherence, viral load (VL) and resistance among outpatients receiving highly active antiretroviral therapy (HAART) in Bangalore, India. In total, 552 outpatients were recruited and VL testing was conducted for all study participants. HIV-1 genotypic resistance testing was performed for 92 participants with a VL > 1000 copies/ml. Interpretation of resistance mutations was performed according to the Stanford database. Past-month adherence and treatment interruptions for >48 h were assessed via self-report. At baseline, 34 participants (6%) reported <95% past-month adherence and 110 (20%) reported a history of >48 h treatment interruptions. Combining the two adherence measures, 22% of participants were classified as 'suboptimally adherent'. In total, 24% of study participants (n=132) had a detectable VL. Among the 92 samples sent for resistance testing, 68% had at least one nucleoside reverse transcriptase inhibitor (NRTI) mutation, with M184 V being the most common (65%) and with 48% having thymidine analogue mutations. Moreover, 72% had at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) mutation and 23% had three or more NNRTI mutations. Both adherence measures were significantly associated with VL (P<0.001). Suboptimal adherence was significantly associated with resistance mutations (P<0.02). The findings illustrate for the first time the strong association between suboptimal adherence, treatment failure and drug resistance to first-line HAART in India. The predictive value of standard adherence measures was improved by including treatment interruption data. The observed mutations can jeopardise future treatment options, especially in light of limited access to second-line treatments. To develop effective adherence interventions, research is needed to examine culturally-specific reasons for treatment interruptions.

Original languageEnglish (US)
Pages (from-to)27-34
Number of pages8
JournalInternational Health
Volume3
Issue number1
DOIs
Publication statusPublished - Mar 2011
Externally publishedYes

    Fingerprint

Keywords

  • Adherence
  • Drug resistance
  • Highly active antiretroviral therapy
  • HIV/AIDS
  • India
  • Virological failure

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Health(social science)

Cite this